Suppr超能文献

相似文献

1
HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12111-6. doi: 10.1073/pnas.1204533109. Epub 2012 Jul 5.
2
Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
J Virol. 2018 May 29;92(12). doi: 10.1128/JVI.00277-18. Print 2018 Jun 15.
4
Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.
PLoS One. 2013 Sep 2;8(9):e74552. doi: 10.1371/journal.pone.0074552. eCollection 2013.
5
Conformational States of a Soluble, Uncleaved HIV-1 Envelope Trimer.
J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.00175-17. Print 2017 May 15.
6
Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies.
J Biol Chem. 2017 Jan 6;292(1):278-291. doi: 10.1074/jbc.M116.725614. Epub 2016 Nov 22.

引用本文的文献

1
Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.
NPJ Vaccines. 2024 Apr 6;9(1):74. doi: 10.1038/s41541-024-00862-8.
2
Microsecond dynamics control the HIV-1 Envelope conformation.
Sci Adv. 2024 Feb 2;10(5):eadj0396. doi: 10.1126/sciadv.adj0396.
3
Modulation of immune responses to liposomal vaccines by intrastructural help.
Eur J Pharm Biopharm. 2023 Nov;192:112-125. doi: 10.1016/j.ejpb.2023.10.003. Epub 2023 Oct 4.
6
Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120.
Cell Chem Biol. 2023 May 18;30(5):540-552.e6. doi: 10.1016/j.chembiol.2023.03.003. Epub 2023 Mar 22.
7
HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier.
Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2215792120. doi: 10.1073/pnas.2215792120. Epub 2023 Feb 16.
8
Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans.
AIDS Res Hum Retroviruses. 2023 Jul;39(7):350-366. doi: 10.1089/AID.2022.0104. Epub 2023 Mar 22.
10
Process development and preclinical evaluation of a major blood stage vaccine candidate, Cysteine-Rich Protective Antigen (CyRPA).
Front Immunol. 2022 Sep 22;13:1005332. doi: 10.3389/fimmu.2022.1005332. eCollection 2022.

本文引用的文献

2
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.
J Virol. 2012 Mar;86(5):2488-500. doi: 10.1128/JVI.06259-11. Epub 2011 Dec 28.
5
Antibody-based protection against HIV infection by vectored immunoprophylaxis.
Nature. 2011 Nov 30;481(7379):81-4. doi: 10.1038/nature10660.
6
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
Nature. 2011 Nov 23;480(7377):336-43. doi: 10.1038/nature10696.
7
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.
Science. 2011 Nov 25;334(6059):1097-103. doi: 10.1126/science.1213256. Epub 2011 Oct 13.
8
Vaccinology: precisely tuned antibodies nab HIV.
Nature. 2011 Sep 21;477(7365):416-7. doi: 10.1038/477416a.
9
Broad neutralization coverage of HIV by multiple highly potent antibodies.
Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验